PTC takes a chance on Sangamo’s Fabry disease gene therapy
BioPharma Dive
Wall Street analysts view the deal as a risky, high-reward bet on a treatment that s nearing a possible regulatory approval and could be superior to existing medications.
pharminent
August 13, 2026 (Last updated: August 18, 2026)
BioPharma Dive
Wall Street analysts view the deal as a risky, high-reward bet on a treatment that s nearing a possible regulatory approval and could be superior to existing medications.
